Figure 3.

Leveraging anti-MICA/B Ab therapeutic efficacy through combination therapies with DDR inducers, HDACi and proteasome inhibitors. The use of DDR inducers, HDACi and proteasome inhibitors may lead to an increased MICA/B synthesis, reduced degradation, and its consequent accumulation on the cell surface. This effect may result in an improved CD16-dependent ADCC of anti-MICA/B Ab, and a recovery of NKG2D-dependent NK cell-mediated cytotoxicity against tumor cells, facilitating the reinstatement of an efficient tumor cell elimination.